Strides to sell majority in Pivot Path to Ascent Capital for Rs 1,000 million

Core Business DivestedMarquee Jv AnnouncedStrategic Transactions View source PDF

STAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+1.7%1-day move

₹1075.10

prior close

₹1099.90

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+1.5+0.6+0.5+1.0+1.7+2.2+5.0+4.7+4.4+0.4-1.9———

Up moveDown movePending

AI summary

Strides Pharma Board approved selling majority stake in subsidiary Pivot Path to Ascent Capital-led consortium for about Rs. 1,000 million. Ascent will also invest Rs. 500 million into Pivot Path. Post-deal, Strides holds 19.95%, making Pivot Path an associate. Pivot Path contributed Rs. 1,447 million (3% of consolidated turnover) in FY26. Sale to close by June 30, 2026; primary infusion by July 31, 2026. Pivot Path is a life sciences consulting and digital services business.

Likely market impact

Strides to receive Rs. 1,000 million cash while losing majority control of subsidiary Pivot Path. Minor revenue impact (3% of turnover), partly offset by cash.